- Tryp Therapeutics recently launched a new website with updated resources to be featured on the site
- Over the next few weeks, the company will share key resources that will be the standout features of the new website
- Tryp believes that the new features represent expanded knowledge of the company’s strategy and will present more opportunities to existing investors and bring in more individuals who share in its course
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) has, since its inception, led the next wave of psychedelic drug development beyond mental health. Its focus on areas of high unmet medical needs and bring relief to millions of people worldwide who are dealing with conditions such as fibromyalgia, CRPS, and Phantom Limb Pain but lack proper treatment for their conditions.
In a move that demonstrates its commitment to taking its operations further and having even a broader market reach, Tryp recently updated its website in an act to better represent the company’s current stage of development. Additionally, it plans to distribute critical resources that will be featured on its updated site, and which will act as a tool for the investment community.
Some of these resources will include an Investor Pack that will cover Tryp’s pitch deck, a factsheet, and a Frequently Asked Questions (“FAQ”) section. There will also be a dedicated FAQ for patients, coupled with a series of short QA videos from the management team.
The updated website will also feature market opportunity info, along with QA with two key individuals. One will be Dr. Jennifer Miller, the Principal Investigator for a clinical trial to treat symptoms associated with eating disorders (https://ibn.fm/DQChR), and the other will be Kevin Boehnke, the Principal Investigator for Phase 2a clinical trial on the treatment of fibromyalgia (https://ibn.fm/Z8RON).
Tryp believes that making these critical resources assessable on the website will present more diligence opportunities to patients suffering from their targeted indications and existing investors. It also believes that by doing so, it will bring in more individuals who will share in its course, allowing them to be part of a movement dedicated to improving millions of lives around the world (https://ibn.fm/rVAHw).
Over the next few weeks, the company provide updates regarding essential resources that will be the standout features of the new website. This is happening in tandem with ushering a new era for psilocybin, with Tryp’s commitment to revolutionizing what psilocybin-based treatments can do with leading-edge therapies for chronic pain and other indications.
For more information, visit the company’s website at www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF
About QualityStocks
QualityStocks is committed to connecting subscribers with companies that have huge potential to succeed in the short and long-term future. It is part of our mission statement to help the investment community discover emerging companies that offer excellent growth potential. We offer several ways for investors to learn more about investing in these companies as well as find and evaluate them.
QualityStocks (QS)
Scottsdale, Arizona
www.qualitystocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the QualityStocks website applicable to all content provided by QS, wherever published or re-republished: http://www.qualitystocks.net/disclaimer.php